A bipartisan group is pushing Health and Human Services Secretary Xavier Becerra to allow imports of cheaper prescription drugs from Canada. Stat, meanwhile, reports on generic manufacturing plant closures’ impact on the Biden administration’s effort to boost drug supplies.
Sens. Amy Klobuchar (D-Minn.), Chuck Grassley (R-Iowa), Angus King (I-Maine) and Susan Collins (R-Maine) sent a letter to the secretary on Monday asking him to back policies permitting states and tribes to import certain prescription drugs from Canada.
In a letter, the senators argued that personal importation could deliver “a critical solution” to lowering medication costs, a goal of the Biden administration. The letter cited that almost 30 percent of adults say they don’t take their prescribed medications due to the cost.
“Americans should be able to obtain affordable medications, and expanding access to safe and affordable drugs in Canada can make a difference by providing direct relief to the millions of Americans who are struggling to afford the increasing cost of prescription drugs,” the letter reads.
“As the Administration considers options for lowering the cost of prescription drugs for patients, we urge your support for permanent solutions that will allow Americans to safely and personally import their medication,” the senators wrote.
The senators specifically called on Becerra to support the Safe and Affordable Drugs from Canada Act, reintroduced by Klobuchar and Grassley in February, that would permit drugs to be imported from the northern country.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh